Catalent Buys Pharmatek Labs, Expands Portfolio

Sept. 13, 2016

Catalent will acquire Pharmatek Laboratories Inc., a San Diego, Calif.-based specialist in drug development and clinical manufacturing. The acquisition will add early-phase drug development capabilities from discovery to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds.

“Catalent continues to expand its industry-leading drug development and delivery technologies to help its pharmaceutical partners to fully unlock the potential of their molecules and provide better treatments for patients,” said Barry Littlejohns, president of Catalent’s Drug Delivery Solutions business.

Pharmatek’s site is a cGMP facility that employs nearly 200 people. It provides development and analytical services for more than 120 molecules annually. Its facility comprises 68,000 square feet of laboratory, manufacturing and support space, with two analytical labs, two formulation labs, four engineering rooms and nine Certified ISO Class 8 manufacturing suites. The site also features 18,000 square feet of laboratory, manufacturing and support space dedicated to development and manufacturing of highly potent compounds.

The transaction is expected to close in the next few weeks. No financial details have been disclosed.